Detalles de la búsqueda
1.
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.
PLoS Pathog
; 18(10): e1010885, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36194628
2.
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
BMC Cancer
; 21(1): 301, 2021 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33757459
3.
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.
Eur J Nucl Med Mol Imaging
; 47(5): 1239-1251, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31754793
4.
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.
Plant Biotechnol J
; 13(8): 1106-20, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26147010
5.
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.
Lancet Infect Dis
; 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38615673
6.
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.
EClinicalMedicine
; 56: 101823, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36684396
7.
Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens.
Front Immunol
; 13: 991509, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36275655
8.
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Trials
; 23(1): 263, 2022 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382844
9.
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
EClinicalMedicine
; 44: 101262, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35043093
10.
Therapy-Induced Senescence Drives Bone Loss.
Cancer Res
; 80(5): 1171-1182, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932453
11.
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis
; 19(10): 1091-1100, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31416692
12.
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
Hum Gene Ther
; 29(9): 1011-1028, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30027768
13.
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens.
Front Immunol
; 8: 595, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28596770
14.
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.
PLoS One
; 11(5): e0152038, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27159166
15.
Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.
Vaccine
; 29(6): 1258-69, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21145913
16.
Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.
PLoS One
; 6(9): e25165, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21984924
17.
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine
; 29(7): 1421-30, 2011 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21187177
18.
Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
Vaccine
; 29(27): 4512-20, 2011 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21514349
Resultados
1 -
18
de 18
1
Próxima >
>>